Literature DB >> 8798976

Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding.

J M Binley1, H J Ditzel, C F Barbas, N Sullivan, J Sodroski, P W Parren, D R Burton.   

Abstract

A large panel of human Fab fragments against the gp41 subunit of the HIV-1 envelope glycoprotein was isolated by panning six phage-displayed antibody libraries against recombinant gp41. The libraries were prepared from HIV-1-seropositive donors. Twenty-three Fabs recognizing conformation-dependent determinants on gp41 were isolated. Further selection of libraries against (1) gp41 ligated with Fabs from the initial selection and against (2) a recombinant gp41-containing gp140 protein yielded five additional Fabs. Competition of members of the Fab panel with one another and with previously described antibodies revealed a series of overlapping specificities that were conveniently grouped into three major epitope clusters. The majority of Fabs recognized epitopes involving residues 649-668 (previously known as the cluster II region), numbered using the Los Alamos LAI sequence. A second set of Fabs reacted with an epitope involving residues 584-609 (known as the cluster I region). Another set of Fabs appeared to recognize a third conformational epitope that has been termed the cluster III region. This third Fab epitope group demonstrated some overlap with both clusters I and II in binding assays. None of the Fabs neutralized HIV-1 laboratory strains at biologically significant concentrations. This tends to support the opinion that a vaccine based on the gp41 molecule has the drawback that neutralizing epitopes of gp41 are rare and/or unfavorably presented to the immune system. Analysis of heavy chain sequences revealed common CDR3 motif sequences in several antibodies, which appears to be an interesting consequence of a persistent immune response to conserved antigen structures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798976     DOI: 10.1089/aid.1996.12.911

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  41 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 3.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Molecular determinants of the human antibody response to HIV-1: implications for disease control.

Authors:  M Viau; M Zouali
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

6.  Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Authors:  Nobuyuki Matoba; Tagan A Griffin; Michele Mittman; Jeffrey D Doran; Annette Alfsen; David C Montefiori; Carl V Hanson; Morgane Bomsel; Tsafrir S Mor
Journal:  Curr HIV Res       Date:  2008-05       Impact factor: 1.581

7.  A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.

Authors:  E Buratti; S G Tisminetzky; P D'Agaro; F E Baralle
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Authors:  Mei-Yun Zhang; Vidita Choudhry; Igor A Sidorov; Vladimir Tenev; Bang K Vu; Anil Choudhary; Hong Lu; Gabriela M Stiegler; Hermann W D Katinger; Shibo Jiang; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Immunol Methods       Date:  2006-10-16       Impact factor: 2.303

10.  Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.

Authors:  Wen Yuan; Xing Li; Marta Kasterka; Miroslaw K Gorny; Susan Zolla-Pazner; Joseph Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.